Latest Regulatory Approval News

Santos Limited has entered a process deed granting XRG Consortium exclusive rights to pursue a potential A$8.89 per share cash takeover offer, setting the stage for a pivotal chapter in the oil and gas sector.

Silk Logistics Holdings and DP World Australia have agreed to push back the deadline for their acquisition deal, awaiting a key regulatory decision from the ACCC.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

Whitebark Energy has finalized a preliminary well design and rig market assessment for drilling the massive Rickerscote prospect in 2026, estimating costs at AU$7.7 million. The move positions the company at the forefront of Australia's emerging hydrogen, helium, and hydrocarbon sectors.

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

Mandalay Resources Corporation has agreed to a plan of arrangement to be acquired by Alkane Resources Limited through its wholly owned subsidiary. Mandalay shareholders will receive 7.875 Alkane shares for each Mandalay share held, creating a combined gold and antimony producer with a strong balance sheet and diversified operations across Australia and Sweden.

Alkane Resources has secured key regulatory approvals from FIRB and ASIC, paving the way for its planned merger with Mandalay Resources. This milestone brings the companies closer to creating a diversified Australian gold and antimony producer.

Duxton Farms Ltd is set to transform its agricultural portfolio through a strategic merger with four private companies, alongside a $4 million placement and a special dividend, aiming to boost scale and diversification.

MIXI Australia has launched a recommended all-cash takeover offer for PointsBet at $1.20 per share, significantly outpacing rival Betr Entertainment’s scrip proposal. The PointsBet board unanimously supports MIXI’s bid, highlighting its certainty and premium value.

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.

Alkane Resources has moved forward with its planned merger with Mandalay Resources, scheduling shareholder meetings for late July to approve the deal that would create a diversified Australian-focused gold and antimony producer.

Stellar Resources reports strong new tin drill results at Queen Hill, supporting resource upgrades and advancing the Heemskirk project towards production readiness.